Anaptysbio Inc (ANAB) - News Archive

AnaptysBio s Rosnilimab Phase 2 Trial Falls Short But Signals Resilience in Immunology Innovation San Diego, Nov. 10, 2025 - In a significant update from AnaptysBio, Inc. (Nasdaq: ANAB), a prominent clinical-stage biote...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company dedicated to developing innovative immunology therapeutics, has recently disclosed promising clinical trial outcomes for two of its lead investigat...

San Diego-based clinical-stage biotechnology company, Anaptys Biosciences, has recently announced the successful completion of a $100 million underwritten registered direct offering. This landmark transaction was led by...

AnaptysBio, a clinical-stage biotechnology company, has recently reported positive top-line results from their Phase 3 clinical trials involving the experimental drug imsidolimab (IL-36R mAb). Designed to address the ch...